These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21421116)

  • 21. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.
    Cronin-Fenton DP; Lash TL
    Expert Rev Clin Pharmacol; 2011 May; 4(3):363-77. PubMed ID: 21709817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
    Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
    BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
    Dezentjé VO; Gelderblom H; Van Schaik RH; Vletter-Bogaartz JM; Van der Straaten T; Wessels JA; Kranenbarg EM; Berns EM; Seynaeve C; Putter H; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2014 Jan; 143(1):171-9. PubMed ID: 24265036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
    Stearns V; Rae JM
    Expert Rev Mol Med; 2008 Nov; 10():e34. PubMed ID: 19019258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inherited gene affects tamoxifen's benefit in some breast cancers.
    Mayo Clin Womens Healthsource; 2006 Jun; 10(6):3. PubMed ID: 16675918
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
    Del Re M; Citi V; Crucitta S; Rofi E; Belcari F; van Schaik RH; Danesi R
    Pharmacol Res; 2016 May; 107():398-406. PubMed ID: 27060675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.
    Ratain MJ; Nakamura Y; Cox NJ
    Clin Pharmacol Ther; 2013 Aug; 94(2):185-7. PubMed ID: 23872831
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Brauch H; Jordan VC
    Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
    Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
    Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.
    Kaplan M; Mahon SM
    Clin J Oncol Nurs; 2013 Apr; 17(2):174-9. PubMed ID: 23538253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline pharmacogenetics of tamoxifen response: have we learned enough?
    Desta Z; Flockhart DA
    J Clin Oncol; 2007 Nov; 25(33):5147-9. PubMed ID: 18024859
    [No Abstract]   [Full Text] [Related]  

  • 35. Tamoxifen and CYP2D6: a contradiction of data.
    Hertz DL; McLeod HL; Irvin WJ
    Oncologist; 2012; 17(5):620-30. PubMed ID: 22531359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
    Seruga B; Amir E
    Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.
    Rae JM
    Clin Pharmacol Ther; 2013 Aug; 94(2):183-5. PubMed ID: 23872830
    [No Abstract]   [Full Text] [Related]  

  • 38. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.
    Drögemöller BI; Wright GEB; Shih J; Monzon JG; Gelmon KA; Ross CJD; Amstutz U; Carleton BC;
    Breast Cancer Res Treat; 2019 Feb; 173(3):521-532. PubMed ID: 30411242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.
    de Vries Schultink AHM; Huitema ADR; Beijnen JH
    Breast; 2018 Dec; 42():38-40. PubMed ID: 30153552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics of tamoxifen therapy.
    Brauch H; Mürdter TE; Eichelbaum M; Schwab M
    Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.